Acute on Chronic Liver Failure and Cirrhosis
Clinical research centers on hospitalized patients with acute on chronic liver failure arising in the setting of cirrhotic liver disease, with attention to severe hepatic decompensation and associated organ failure.
- Hepatic failure
- Systemic inflammation
- Organ dysfunction
The therapeutic interest in this area is focused on improving outcomes in advanced liver disease with high short-term mortality.
Cell-based Liver Therapy
Research activity includes cell therapy for liver disorders, with a focus on HepaStem as an investigational treatment in patients with severe liver insufficiency.
- Mesenchymal-like cell therapy
- Infusion-based treatment
- Hepatic regeneration
This area reflects interest in therapies intended for complex hepatic disease with limited treatment options.
Long-term Safety Follow-up
The sponsor also supports follow-up research evaluating the long-term safety of prior HepaStem exposure in participants from earlier interventional studies.
- Post-treatment monitoring
- Durability of safety
- Extended patient observation
These studies include individuals previously treated for urea cycle disorders, Crigler-Najjar syndrome, and fibroinflammatory liver disease.
Inherited and Fibroinflammatory Liver Disorders
Additional therapeutic interest extends to rare metabolic liver diseases and fibroinflammatory conditions, especially urea cycle disorders and Crigler-Najjar syndrome.
- Rare liver disease
- Metabolic hepatology
- Chronic fibroinflammatory injury
These areas connect the sponsor’s clinical portfolio to both acute and chronic forms of liver pathology.
